Whole-Cell In Vitro Models Can Predict Clinically-Relevant Herb-Drug Interactions
As herbal-based dietary supplement usage continues to increase, including among patients using prescription medicines, the potential for herb-drug interactions (HDIs) also increases. Patients and their physicians need more information on how botanical supplements could affect the safety and efficacy of drugs. Clinical studies are not always feasible, and conventional in vitro models have shown poor IVIVC.
- A physiologically-relevant model used to predict clinically-relevant HDIs. Study results were published in DMD Sep, 2017, “Prediction of Clinically Relevant Herb-Drug Clearance Interactions Using Sandwich-Cultured Human Hepatocytes: Schisandra spp. Case Study.”*
- Application of SCHH for studying the types of complex mixtures represented by herbal extracts.
- Application of the model approach to other complex mixtures and toxicity endpoints.
*This research was supported by P&G and conducted at BioIVT’s laboratory in Durham, NC.
Click here to register.
Dr. Amy Roe, Senior Toxicologist, The Procter and Gamble Company
Dr. Roe has over 20 years of experience as a practicing toxicologist in government, pharmaceutical, and consumer product industries, through positions at both the U.S. FDA (NCTR) and The Procter & Gamble Company. Her expertise includes drug / xenobiotic metabolism and pharmacokinetics and she has led toxicology programs in support of drugs, medical devices, herbal & dietary supplements, foods and water filtration devices.